Last reviewed · How we verify
Thalidomide, Dexamethasone
Thalidomide inhibits the release of tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in inflammation and immune response.
Thalidomide inhibits the release of tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in inflammation and immune response. Used for Multiple myeloma, Erythema nodosum leprosum.
At a glance
| Generic name | Thalidomide, Dexamethasone |
|---|---|
| Sponsor | Grupo de Estudos Multicentricos em Onco-Hematologia |
| Drug class | Anti-inflammatory, Immunomodulator |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Thalidomide works by binding to and inhibiting the release of TNF-alpha, a key cytokine involved in the inflammatory response. This action helps to reduce inflammation and modulate the immune response, which can be beneficial in treating certain types of cancer. Additionally, thalidomide has been shown to have anti-angiogenic properties, which can help to prevent the growth of new blood vessels that feed tumors.
Approved indications
- Multiple myeloma
- Erythema nodosum leprosum
Common side effects
- Neuropathy
- Fatigue
- Dizziness
- Constipation
- Headache
Key clinical trials
- The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM (PHASE4)
- EDOCH Alternating With DHAP for New Diagnosed Younger MCL (PHASE4)
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (PHASE3)
- Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. (PHASE2)
- ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial (PHASE4)
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma (PHASE3)
- ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (PHASE2)
- Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: